Juan Carlos Caballero Berrocal
A5063678115- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
Complejo Hospitalario de Salamanca
2019-2024
Instituto de Investigación Biomédica de Salamanca
2019
Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating benefits and risks of HSCT MDS, timing being a crucial question. Here, we aimed to develop validate decision support system define optimal MDS on basis clinical genomic information as provided by Molecular International Prognostic Scoring System (IPSS-M).
Summary Patients with low‐risk myelodysplastic syndromes (MDS) usually develop iron overload. This leads to a high level of oxidative stress in the bone marrow (BM) and increases haematopoietic cell dysfunction. Our objective was analyse whether chelation deferasirox (DFX) alleviates consequences improves BM functionality. We analysed 13 iron‐overloaded MDS patients' samples before 4–10 months after treatment DFX. Using multiparametric flow cytometry analysis, we measured intracellular...